Jeanne Mason - Baxter International Senior Vice President - Human Resources
| BAX Stock | USD 41.02 0.62 1.53% |
President
Dr. Jeanne K. Mason Ph.D., is Senior Vice President Human Resources of the Company. Ms. Mason joined Baxter in 2006 from GE Insurance Solutions, a primary insurance and reinsurance business, where she was responsible for global human resource functions. Ms. Mason began her career with General Electric in 1988 after serving with the U.S. General Accounting Office in Washington, D.C. Her GE experience included leadership roles in Europe for GE Information Services and GE Capital Real Estate. since 2017.
| Age | 68 |
| Tenure | 7 years |
| Address | One Baxter Parkway, Deerfield, IL, United States, 60015 |
| Phone | 224 948 2000 |
| Web | https://www.baxter.com |
Baxter International Management Efficiency
The company has Return on Asset of 0.0334 % which means that on every $100 spent on assets, it made $0.0334 of profit. This is way below average. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Baxter International's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Sousa | HealthStream | 55 | |
| Angelique Hill | HealthEquity | 55 | |
| Trisha Coady | HealthStream | 48 | |
| William Otten | HealthEquity | 52 | |
| Steven Jackson | National Research Corp | 42 | |
| Delano Ladd | HealthEquity | 43 | |
| Kevin Karas | National Research Corp | 60 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Scott McQuigg | HealthStream | 50 | |
| Edward Pearson | HealthStream | 61 | |
| Gary Robinson | HealthEquity | 55 | |
| Mollie Condra | HealthStream | N/A | |
| Michael Collier | HealthStream | 48 | |
| Jonathan Soldan | HealthEquity | 32 | |
| Larry Trittschuh | HealthEquity | 52 | |
| Thomas Schultz | HealthStream | 49 | |
| Edward Bloomberg | HealthEquity | 41 | |
| Frode Jensen | HealthEquity | 64 | |
| Ashley Dreier | HealthEquity | 44 | |
| Jeffery Doster | HealthStream | 51 | |
| Jeffrey Cunningham | HealthStream | 57 | |
Management Performance
| Return On Equity | -0.0096 | ||||
| Return On Asset | 0.0334 |
Baxter International Leadership Team
Elected by the shareholders, the Baxter International's board of directors comprises two types of representatives: Baxter International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Baxter. The board's role is to monitor Baxter International's management team and ensure that shareholders' interests are well served. Baxter International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Baxter International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Rosenbloom, Executive Counsel | ||
| Jacqueline Kunzler, Senior Vice President and Chief Quality Officer | ||
| Sebastian Bufalino, Principal Accounting Officer, Corporate VP and Controller | ||
| Brik Eyre, Senior Vice President, President - Americas | ||
| Heather Knight, Executive Therapies | ||
| Talvis Love, Senior Officer | ||
| Amy McbrideWendell, Independent Director | ||
| Jeanne Mason, Senior Vice President - Human Resources | ||
| Brian Stevens, Senior Vice President Chief Accounting Officer, Controller | ||
| Kornelis Storm, Independent Director | ||
| Karp, Corporate Vice President Controller | ||
| Cathy Smith, Independent Director | ||
| Marcus Schabacker, Chief Scientific Officer, Corporate Vice President | ||
| Thomas Chen, Independent Director | ||
| Clare Trachtman, Vice President Investor Relations | ||
| Amy Wendell, Independent Director | ||
| Peter Hellman, Lead Independent Director | ||
| Robert Parkinson, Chairman, CEO and Pres | ||
| MS MD, Senior Officer | ||
| Christopher Toth, Executive Care | ||
| Giuseppe Accogli, Senior Vice President and Presidentident - Global Businesses | ||
| Sean Martin, Corporate Vice President General Counsel | ||
| Cristiano Franzi, Senior Vice President and President EMEA | ||
| Carole Shapazian, Independent Director | ||
| Andrew Frye, Senior Vice President and President APAC | ||
| Nancy Schlichting, Independent Director | ||
| Robert Hombach, CFO and Corporate VP | ||
| Michael Mahoney, Independent Director | ||
| Jill Schaaf, Corporate Vice President and President - Renal | ||
| Stacey Eisen, Senior Communications | ||
| Ludwig Hantson, Corporate VP and President of BioScience | ||
| Gail Fosler, Independent Director | ||
| John Forsyth, Independent Director | ||
| Timothy Lawrence, Corporate VP of Operations | ||
| Uma Chowdhry, Independent Director | ||
| Scott Pleau, Corporate Vice President - Operations | ||
| David Wilkes, Independent Director | ||
| Albert Stroucken, Lead Independent Director | ||
| Paul Vibert, President Corporate Vice President - International | ||
| James Borzi, Senior Vice President Chief Supply Chain Officer | ||
| Mba BE, Executive Pharmaceuticals | ||
| James Gavin, Independent Director | ||
| Ellen Bradford, Senior Secretary | ||
| Piero Novello, Senior Markets | ||
| Blake Devitt, Independent Director | ||
| Reazur Rasul, Executive Technologies | ||
| Gerard Greco, Senior Officer | ||
| Jose Almeida, Chairman of the Board, President, Chief Executive Officer | ||
| James Saccaro, Chief Financial Officer, Executive Vice President | ||
| Thomas Stallkamp, Lead Independent Director | ||
| David Scharf, Corporate VP, General Counsel and Corporate Secretary | ||
| Robert Felicelli, Corporate Vice President - Quality | ||
| Wayne Hockmeyer, Independent Director | ||
| Patricia Morrison, Independent Director | ||
| Joel Grade, Executive CFO | ||
| Stephen Oesterle, Independent Director | ||
| Munib Islam, Independent Director |
Baxter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Baxter International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0096 | ||||
| Return On Asset | 0.0334 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 31.75 B | ||||
| Shares Outstanding | 509.35 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 92.46 % | ||||
| Number Of Shares Shorted | 7.62 M | ||||
| Price To Earning | 27.05 X |
Pair Trading with Baxter International
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Baxter International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Baxter International will appreciate offsetting losses from the drop in the long position's value.Moving against Baxter Stock
| 0.63 | ICCM | Icecure Medical Financial Report 27th of May 2024 | PairCorr |
| 0.58 | SINT | SINTX Technologies | PairCorr |
| 0.54 | SRDX | SurModics Earnings Call Next Week | PairCorr |
| 0.51 | SIBN | Si Bone Financial Report 6th of May 2024 | PairCorr |
| 0.5 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Baxter International could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Baxter International when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Baxter International - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Baxter International to buy it.
The correlation of Baxter International is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Baxter International moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Baxter International moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Baxter International can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Baxter International. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Baxter Stock please use our How to Invest in Baxter International guide.Note that the Baxter International information on this page should be used as a complementary analysis to other Baxter International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Baxter Stock analysis
When running Baxter International's price analysis, check to measure Baxter International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baxter International is operating at the current time. Most of Baxter International's value examination focuses on studying past and present price action to predict the probability of Baxter International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Baxter International's price. Additionally, you may evaluate how the addition of Baxter International to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Baxter International's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Baxter International. If investors know Baxter will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Baxter International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.338 | Dividend Share 1.16 | Earnings Share (0.15) | Revenue Per Share 29.275 | Quarterly Revenue Growth 0.037 |
The market value of Baxter International is measured differently than its book value, which is the value of Baxter that is recorded on the company's balance sheet. Investors also form their own opinion of Baxter International's value that differs from its market value or its book value, called intrinsic value, which is Baxter International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Baxter International's market value can be influenced by many factors that don't directly affect Baxter International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Baxter International's value and its price as these two are different measures arrived at by different means. Investors typically determine if Baxter International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Baxter International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.